Start with your disease setting, scans, testosterone status and prior treatment. A rising PSA does not by itself tell you whether a study requires local recurrence, distant metastases or castration-resistant disease. BRCA/HRR, PTEN and PSMA tests can matter, but their requirements differ by study.
Answer a few questions to find clinical trials matched to your specific Prostate Cancer situation.
A thorough search takes ~15 minutes — we'll email your results. No sign-up.
Localized or regional disease: cancer confined to the prostate or regional tissues/nodes; studies may involve primary treatment or postoperative radiation.
Biochemical recurrence (BCR): PSA rises after prior local treatment. Imaging and prior treatments determine which recurrence studies apply.
mHSPC / mCSPC: metastatic hormone- or castration-sensitive disease; newer labels may call this androgen pathway modulation-naïve or -sensitive disease.
mCRPC: metastatic disease progressing despite castrate testosterone. Prior AR-pathway drugs, chemotherapy and radioligand treatment often determine the cohort.
Current Clinical Trial Landscape
Registry snapshot, November 14, 2026: a worldwide ClinicalTrials.gov query for Prostate Cancer, interventional studies, overall status Recruiting, returned 937 records. This is a broad search result, not 937 suitable options for one person. Site and cohort availability vary. Open the filtered registry search.
Selected research areas:
PSMA-directed: 177Lu-PSMA-617 and 177Lu-TLX591 beta emitters; 225Ac agents such as AZD2265 / FPI-2265 and AAA817, PSMA PET-guided treatment, PSMA bispecifics
AR-pathway and related agents: next-gen anti-androgens (enzalutamide, apalutamide, darolutamide, rezvilutamide, HC-1119), AR degraders, CYP11A1 (opevesostat), EZH2 (mevrometostat), combination intensification
Bispecific T-cell engagers: xaluritamig (STEAP1xCD3), pasritamig (PSMAxCD3) — first wave reaching Phase 3 in mCRPC
PARP / BRCA / HRR-directed: olaparib (Lynparza), talazoparib (Talzenna) + enzalutamide TALAPRO-2 FDA Jun 2023, rucaparib (Rubraca), niraparib (Zejula) + androgen ablation after primary radiotherapy for selected high-risk localized or locally advanced disease (NCT04947254, Phase 2; an investigational setting), saruparib NCT06952803 vs RT/ADT high-risk BRCA prostate. See the PARP Inhibitors mechanism hub.
ADCs including ifinatamab deruxtecan (B7-H3/CD276-targeting, I-DXd) and BL-B01D1; checkpoint immunotherapy combinations
→ For a focused, deeper view of the castration-resistant setting — PSMA radioligands, PARP/HRR combinations, next-gen AR agents, and PSMA/PSCA/STEAP1 cell therapies, with the Pluvicto evidence and biomarker guidance — see the dedicated metastatic castration-resistant prostate cancer (mCRPC) trials page.
Selected Trials by Disease Setting
All 37 cited registry records were checked November 14, 2026: 33 recruiting, three not yet recruiting, and one active but not recruiting. Studies not open to new enrollment are separated below. These are selected examples; overall recruitment does not guarantee an open site, cohort or personal eligibility.
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
ADT + AR-pathway inhibitor ± docetaxel is standard; 2026 added Pluvicto + ARPI for PSMA-positive disease (PSMAddition) and capivasertib + abiraterone for PTEN-deficient disease (CAPItello-281). Trials explore intensification and PSMA-based approaches:
Triplet therapy / intensification:
NCT06931340 - ADT + Apalutamide ± Docetaxel in metastatic prostate cancer (Phase 3)
NCT05983783 - Rezvilutamide + ADT + Docetaxel vs Rezvilutamide + ADT in mHSPC (Phase 3)
NCT07333066 - REINFORCE: adding docetaxel after an inadequate deep PSA response to initial apalutamide-based treatment in mHSPC (Phase 3; protocol timing applies)
PSMA-directed in mHSPC:
NCT06496581 - PEACE6: SOC ± 177Lu-PSMA-617 in de novo mHSPC with poor PSA response (Phase 3)
De-escalation:
NCT07260435 - Shorter treatment with ARPI in low-volume mHSPC (Phase 3)
Suboptimal response:
NCT06592924 - Adding docetaxel to ARPI in mCSPC with suboptimal PSA response (Phase 3)
NCT03678025 - Standard systemic therapy ± definitive treatment in metastatic prostate cancer (Phase 3)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The most active research area in 2026. Phase 3 trials span bispecifics, PSMA radioligands (now including alpha-emitter 225Ac), AR-pathway intensification, and new ADCs:
Bispecific T-cell engagers:
NCT07213674 - Xaluritamig (STEAP1xCD3) + Abiraterone vs investigator's choice in chemo-naive mCRPC (Phase 3)
NCT07164443 - Pasritamig (PSMAxCD3) vs Placebo in late-line mCRPC (Phase 3)
NCT07225946 - Pasritamig + Docetaxel vs Docetaxel in mCRPC (Phase 3)
Next-gen AR-targeted:
NCT06136650 - Opevesostat (CYP11A1 inhibitor, MK-5684) vs alternative NHA in mCRPC post one NHA (Phase 3)
NCT06629779 - Mevrometostat (PF-06821497, EZH2 inhibitor) + Enzalutamide vs Enzalutamide alone in ARSi-naive mCRPC (Phase 3)
NCT07723248 - Himalayas-1: rinzimetostat (ORIC-944, EZH2 inhibitor) + darolutamide versus an ARPI or docetaxel control in mCRPC previously treated with abiraterone (Phase 3)
NCT03851640 - HC-1119 (next-gen anti-androgen) in mCRPC (Phase 3)
PSMA radioligand therapy (177Lu and newer 225Ac):
NCT07611110 - VECTRA-01: AZD2265 (FPI-2265, 225Ac-PSMA-I&T alpha radioligand) vs SOC in PSMA-positive mCRPC (Phase 3)
NCT06855277 - AAA817 (225Ac-PSMA-617) + ARPI vs SOC in PSMA-positive mCRPC, first-line setting (Phase 3)
NCT06780670 - AAA817 vs standard of care in previously treated PSMA-positive mCRPC after 177Lu-PSMA (Phase 2/3)
NCT06520345 - ProstACT Global: 177Lu-TLX591 + SOC vs SOC alone in mCRPC (Phase 3)
Antibody-drug conjugates:
NCT06925737 - IDeate-Prostate01: ifinatamab deruxtecan (B7-H3 ADC, I-DXd / MK-2400) versus docetaxel in mCRPC after ARPI treatment (Phase 3)
Post-NHA chemotherapy comparator:
NCT07365995 - BNT324 vs Docetaxel in mCRPC (Phase 3, activated 2026-06-27 — BioNTech ADC challenger to docetaxel post-NHA standard, joining QLC5508 as a second Phase 3 in the mCRPC post-NHA chemo-comparator space)
Platform / biomarker-driven:
NCT03903835 - ProBio: Biomarker-driven multi-arm platform trial in metastatic prostate cancer (Phase 3)
CRPC With Limited Metastases on Functional Imaging
NCT06276465 - Darolutamide ± stereotactic radiation in castration-resistant disease with limited metastases on functional imaging (Phase 3)
BRCA / HRR-Mutated Prostate Cancer
For men with germline or somatic BRCA1/2 or other HRR-pathway mutations. Olaparib + abiraterone is already approved first-line in BRCA-mutated mCRPC; trials below extend PARP and platinum strategies earlier in the disease course:
NCT06952803 - EvoPAR-Prostate02: saruparib (AZD5305) + RT/ADT versus placebo + RT/ADT in centrally confirmed BRCA1/2-mutated high-risk localized/locally advanced disease or selected high-risk BCR after prostatectomy (Phase 3; protocol imaging and timing apply)
Biochemical Recurrence / Oligometastatic
NCT04794777 - Salvage RT vs PSMA PET/CT-targeted treatment in relapsing prostate cancer (Phase 3)
NCT05352178 - Metastasis-directed therapy for oligorecurrent prostate cancer (Phase 3)
NCT04423211 - Apalutamide + PET-guided targeted radiation for prostate cancer recurring after surgery (Phase 3)
NCT05939414 - 177Lu-vipivotide tetraxetan vs Observation in PSMA+ oligometastatic prostate cancer (Phase 3)
Localized / Regional / Post-Surgery
NCT05116475 - Darolutamide + ADT + radiation in newly diagnosed pelvic-node-positive (N1), non-distant-metastatic (M0) prostate cancer (Phase 3)
NCT05946213 - Shorter duration vs usual radiation in high-risk prostate cancer (Phase 3)
Investigational PARP Strategy After Primary Radiation
NCT04947254 — androgen ablation with or without niraparib after primary radiotherapy in selected high-risk localized/locally advanced disease (Phase 2; recruiting). This is not a general post-radiation biochemical-recurrence study.
Studies Not Open to New Enrollment
NCT07641855 - BL-B01D1 combination therapy in mCRPC (Phase 2/3, not yet recruiting)
NCT07632690 - QLC5508 vs Docetaxel in mCRPC after progression on novel hormonal agents (Phase 3, not yet recruiting)
NCT07591467 - Carboplatin-enhanced therapy in BRCA-mutated or neuroendocrine-differentiated aggressive metastatic castration-sensitive prostate cancer (Phase 3, not yet recruiting)
NCT04787744 - Standard systemic therapy ± PET-directed local therapy for oligometastatic prostate cancer (Phase 2/3 — active, not recruiting as checked November 14, 2026)
Not yet recruiting is different from an open study. Active, not recruiting means follow-up or treatment may continue without new enrollment; confirm changes with the study team.
Novel Approaches
Alpha-emitter PSMA radioligand therapy: First Phase 3 trials of 225Ac-PSMA agents — AZD2265 / FPI-2265 (VECTRA-01) and AAA817 / 225Ac-PSMA-617 — moving beyond the established beta-emitter 177Lu-PSMA-617
Bispecific T-cell engagers: Xaluritamig (STEAP1xCD3) and pasritamig (PSMAxCD3) — first BiTEs reaching Phase 3 in prostate cancer. Xaluritamig now being tested earlier in chemo-naive mCRPC (with abiraterone) and pasritamig is in late-line and docetaxel-combination Phase 3s
PSMA radioligand therapy expansion: Moving from late-line mCRPC into first-line mCRPC (AAA817 + ARPI), de novo mHSPC with poor PSA response (PEACE6), and oligometastatic settings (177Lu-vipivotide vs observation)
AR-pathway intensification through new mechanisms: Opevesostat (CYP11A1 inhibitor), mevrometostat (EZH2 inhibitor), rezvilutamide, HC-1119 — targeting AR signaling through orthogonal pathways
PARP earlier in disease course: Saruparib + RT/ADT in high-risk localized BRCA-mutated prostate cancer — moving PARP from mCRPC into the curative-intent setting for BRCA-positive men
PSMA PET-guided treatment: Multiple Phase 3 trials using PSMA PET to guide radiation, surgery, and systemic therapy decisions
Frequently Asked Questions
How do I find prostate cancer clinical trials?
Start with disease setting, recent scans, PSA and testosterone results, prior surgery/radiation and the exact AR-pathway drugs, chemotherapy or radioligand therapy you have received. Add BRCA/HRR, PTEN and PSMA results you know. ClinTrialFinder suggests studies for discussion; a study team confirms eligibility and availability.
How many prostate cancer trials are recruiting?
The November 14, 2026 worldwide ClinicalTrials.gov query for Prostate Cancer, interventional studies and Recruiting status returned 937 records. This broad registry result is not the number suitable for one person. The selected studies here have separately checked recruitment labels.
Which trials are for hormone-sensitive versus castration-resistant disease?
mHSPC/mCSPC studies and mCRPC studies address different settings. mCRPC requires progression despite castrate testosterone; prior AR-pathway, taxane and PSMA-radioligand exposure can further define a cohort. Do not substitute a trial from the other setting based only on a metastatic prostate cancer diagnosis.
Are there trials for rising PSA after prostate surgery or radiation?
Yes, selected recurrence studies include PSMA-directed salvage approaches (NCT04794777), PET-guided apalutamide/radiation after surgery (NCT04423211), and PROSTATE-IQ (NCT06274047). Imaging, prior local treatment, PSA level and treatment timing matter. A rising PSA alone does not establish distant metastatic or castration-resistant disease.
Do all BRCA, HRR, PTEN or PSMA findings open the same trials?
No. Those are different biomarkers and selection tests. EvoPAR-Prostate02 (NCT06952803), for example, requires centrally confirmed BRCA1/2 mutation plus a defined disease setting. A PSMA radioligand trial may require protocol-specific PET findings and prior treatment. Check the exact test and cohort rather than assuming a broad positive result is enough.
This page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or healthcare team. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here.